=> fil hcaplu
FILE 'HCAPLUS' ENTERED AT 12:01:25 ON 10 APR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 Apr 2002 VOL 136 ISS 15
FILE LAST UPDATED: 8 Apr 2002 (20020408/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

The P indicator for Preparations was not generated for all of the CAS Registry Numbers that were added to the CAS files between 12/27/01 and 1/23/02. As of 1/23/02, the situation has been resolved. Searches and/or SDIs in the H/Z/CA/CAplus files incorporating CAS Registry Numbers with the P indicator executed between 12/27/01 and 1/23/02 may be incomplete. See the NEWS message on this topic for more information.

=> d stat que
L1 16 SEA FILE=HCAPLUS ("FISH FALK"/AU OR "FISH FALK"/IN)

=> d ibib abs hitrn l1 1-16

L1 ANSWER 1 OF 16 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:256595 HCAPLUS
TITLE: Method and kit for the transdermal determination of analyte concentration in blood
INVENTOR(S): **Fish, Falk**
PATENT ASSIGNEE(S): Israel
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002027326	A2	20020404	WO 2001-IL848	20010906

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IL 2000-138788 A 20000929

AB A method is provided for detg. the level of an analyte in the blood of an individual by measuring the level of the analyte in an interstitial fluid or in any other non blood fluid which does not contain red blood cells and adjusting the measurement value by the concn. of at least one ref. analyte.

IT INDEXING IN PROGRESS

L1 ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:145112 HCAPLUS
DOCUMENT NUMBER: 132:177744
TITLE: Method and kit for the determination of analyte concentration in blood based on detn. in non-blood sample
INVENTOR(S): **Fish, Falk**
PATENT ASSIGNEE(S): Israel
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000011469	A1	20000302	WO 1999-IL447	19990819

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

IL 125880	A1	20001121	IL 1998-125880	19980821
AU 9953001	A1	20000314	AU 1999-53001	19990819
EP 1105727	A1	20010613	EP 1999-938497	19990819

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: IL 1998-125880 A 19980821
WO 1999-IL447 W 19990819

AB A method is provided for detg. the level of an analyte in the blood of an individual based on detn. of the level of the same analyte in a non-blood sample (e.g. urine, saliva and hair) obtained from the individual. The non-blood sample contains red blood cells and the vol. of the blood in the sample together with the amt. of the analyte in the sample are the basis for calcg. the level of the analyte in the individual's blood. Kits for carrying out the above method are also provided. Glucose and Hb calibration values were obtained from testing dild. std. glucose and Hb solns. using a Sigma Chems. colorimetric glucose test kit and a Pierce PowerSignal ELISA Chemiluminescent assay. A calibration equation is derived and used in the detn. of the level of glucose and Hb in a hair follicle sample.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:420736 HCAPLUS
DOCUMENT NUMBER: 122:182735
TITLE: Apparatus for dry chemical analysis of fluids
INVENTOR(S): **Fish, Falk**
PATENT ASSIGNEE(S): Orgenics Ltd., Israel
SOURCE: U.S., 7 pp. Cont.-in-part of U.S. Ser. No. 816,280, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5389338	A	19950214	US 1993-101965	19930804
IL 96887	A1	19960804	IL 1991-96887	19910106
PRIORITY APPLN. INFO.:			IL 1991-96887	19910106
			US 1992-816280	19920103

AB App. is proposed for dry chem. anal. of fluids, e.g., blood, that comprises a filter, a filter holder app. including a base member defining a filter supporting location and a filter retaining app. including a mesh arranged to retain the filter at the filter supporting location in spaced relation with respect to the mesh.

L1 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1992:542545 HCAPLUS
DOCUMENT NUMBER: 117:142545
TITLE: Filter apparatus for dry analysis of fluids
INVENTOR(S): **Fish, Falk**
PATENT ASSIGNEE(S): Orgenics International Holdings B.V., Neth.
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9212425	A1	19920723	WO 1992-NL2	19920106
W: JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
IL 96887	A1	19960804	IL 1991-96887	19910106
EP 565594	A1	19931020	EP 1992-902939	19920106
EP 565594	B1	19950607		
R: CH, DE, ES, FR, LI, NL				
JP 06504621	T2	19940526	JP 1992-503110	19920106
JP 2958115	B2	19991006		
ES 2073285	T3	19950801	ES 1992-902939	19920106
PRIORITY APPLN. INFO.:			IL 1991-96887	19910106
			WO 1992-NL2	19920106

AB App. for dry anal. of fluids comprises a filter, a filter-holder app. including a base member defining a filter-supporting location and a filter-retaining app. including a mesh arranged to retain the filter at the filter supporting location in spaced relationship with respect to the mesh.

L1 ANSWER 5 OF 16 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1992:147115 HCAPLUS
DOCUMENT NUMBER: 116:147115
TITLE: Field operable devices for immunological, molecular and toxicological diagnosis - a review on a unified approach
AUTHOR(S): **Fish, Falk**
CORPORATE SOURCE: Orgenics Ltd., Yavne, Israel
SOURCE: Biotechnol.: Bridging Res. Appl., Proc. U.S.-Isr. Res. Conf. Adv. Appl. Biotechnol. (1991), Meeting Date 1990, 179-204. Editor(s): Kamely, Daphne; Chakrabarty, Ananda M.; Kornguth, Steven E. Kluwer: Boston, Mass.
CODEN: 57MWA2
DOCUMENT TYPE: Conference; General Review
LANGUAGE: English
AB A review with many refs. on the principles, construction, and performance devices incorporating the unified approach. The Comb unified package concept for diagnosis is discussed in detail.

L1 ANSWER 6 OF 16 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1991:513269 HCAPLUS
DOCUMENT NUMBER: 115:113269
TITLE: Microbiological assay kit and method for detecting antibacterial compounds
INVENTOR(S): Reinhartz, Avraham; Aldadjem, Sarah; **Fish, Falk**
PATENT ASSIGNEE(S): Orgenics Ltd., Israel
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 418113	A2	19910320	EP 1990-402409	19900831
EP 418113	A3	19910502		

R: BE, DE, ES, FR, GB, IT, NL

PRIORITY APPLN. INFO.: IL 1989-91596 19890911

AB A method for detecting residual antibacterial substances in a sample comprises contacting the sample with viable bacteria followed by detecting the microbial growth using a chromogenic compd. The method is particularly useful in detecting residual antibiotics in food or dairy products. A detection kit comprises viable bacteria, reagents for enhancing the sensitivity of the bacteria to the antibacterial compd., and a growth medium. Penicillin G in milk was detected using lyophilized Streptococcus thermophilus cultured in a hypotonic medium contg. 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) which developed a blue-red color upon microbial redn. MTT can also be detd. at 570 nm after butanol or fluorocarbon extn. The sensitivity of this method was 1 penicillin mIU/mL.

L1 ANSWER 7 OF 16 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1989:420540 HCAPLUS
DOCUMENT NUMBER: 111:20540
TITLE: Reversed competitive solid phase immunoassay for detecting single-epitope analytes and kit therefor
INVENTOR(S): **Fish, Falk**
PATENT ASSIGNEE(S): Orgenics Ltd., Israel
SOURCE: Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 296036	A2	19881221	EP 1988-401425	19880610
EP 296036	A3	19910529		

R: BE, DE, ES, FR, GB, IT, NL

JP 01221665	A2	19890905	JP 1988-149162	19880615

PRIORITY APPLN. INFO.: IL 1987-82873 19870615

AB The present invention relates to a solid-phase competitive immunoassay method for detecting (single-epitope) analytes, comprising: (a) coating a surface with antibodies against the analyte to be detd.; (b) contacting the coated surface with an aq. sample contg. the analyte to be analyzed and with a conjugate of the analyte with a carrier so as to effect binding between (i) the antibodies and the analyte, and (ii) the antibodies and the analyte-carrier conjugate; (c) removing the soln. contg. antibody-analyte and antibody-conjugate complexes; and (d) measuring the amt. of analyte-carrier conjugate remaining in the soln. of step (c) to indicate the amt. of the analyte in the sample. Two assay kits are designed.

L1 ANSWER 8 OF 16 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1987:493397 HCAPLUS
DOCUMENT NUMBER: 107:93397
TITLE: Phase variation in Bordetella pertussis is accompanied by changes in DNA modification
AUTHOR(S): Goldman, Sarah; Navon, Yehudit; **Fish, Falk**
CORPORATE SOURCE: Fac. Life Sci., Tel Aviv Univ., Tel Aviv-Jaffa, 69978, Israel
SOURCE: Microb. Pathog. (1987), 2(5), 327-38
CODEN: MIPAEV; ISSN: 0882-4010
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Pathogenic strains of B. pertussis tend to undergo a phase variation process when propagated in vitro. The phase variants do not express part or all of the virulence factors of the pathogenic strain and are phenotypically stable. In an attempt to characterize the mol. changes accompanying phase variation, chromosomal DNA, isolated from B. pertussis and its variants, was digested with a variety of restriction enzymes followed by agarose gel electrophoresis. While variant DNA was digested by all tested enzymes, pathogenic strain DNA was not digested by part of the enzymes, thus suggesting modification of the DNA at specific sites. DNA isolated from reversible, growth medium-induced variants demonstrated sensitivity to digestion identical to that of spontaneous, stable variants. Anal. of the restriction sequences of all the enzymes which did not digest DNA from pathogenic strains failed to reveal any common sequence known to be affected by methylation. HPLC and nearest-neighbor anal. showed a 2-fold increase in the level of DNA methylation in the pathogenic strain. It was concluded that (a) the chromosomal DNA in virulent strains of B. pertussis is protected against enzymic digestion by an as yet unknown modification and (b) variation in B. pertussis may be caused by changes in the modification of the DNA rather than by mutation.

L1 ANSWER 9 OF 16 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1987:420349 HCAPLUS
DOCUMENT NUMBER: 107:20349
TITLE: System for solid-phase immunological determination
INVENTOR(S): **Fish, Falk**; Herzberg, Max; Ritterband, Menachem
PATENT ASSIGNEE(S): Orgenics Ltd., Israel
SOURCE: Fr. Demande, 49 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2573872	A1	19860530	FR 1985-17533	19851127
FR 2573872	B1	19881014		
JP 61181965	A2	19860814	JP 1985-263948	19851126
JP 08023558	B4	19960306		
IL 77144	A1	19910415	IL 1985-77144	19851126
US 5126276	A	19920630	US 1987-113395	19871019

PRIORITY APPLN. INFO.: US 1984-675439 19841127

AB A durable and storable recording system is described for quant. and/or qual. detn. of an analyte. It comprises a solid support on which several receptors are bound, .gtoreq.2 of which are conjugated to the same analyte. The system can be used to detect nucleic acids, antigens, and antibodies.

L1 ANSWER 10 OF 16 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1986:203488 HCAPLUS
DOCUMENT NUMBER: 104:203488
TITLE: Method and apparatus for assaying with optional reagent quality control
INVENTOR(S): Herzberg, Max; **Fish, Falk**
PATENT ASSIGNEE(S): Orgenics Ltd., Israel
SOURCE: Eur. Pat. Appl., 72 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 171150	A2	19860212	EP 1985-304197	19850612
EP 171150	A3	19870701		
EP 171150	B1	19920325		
EP 171150	B2	19980902		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
IL 75464	A1	19900831	IL 1985-75464	19850610
JP 61082166	A2	19860425	JP 1985-129103	19850612
ES 544079	A1	19870116	ES 1985-544079	19850612
AT 74210	E	19920415	AT 1985-304197	19850612
PRIORITY APPLN. INFO.:			US 1984-619739	19840612
			EP 1985-304197	19850612

AB A solid-phase immunoassay system and method are described for the detection and measurement of multiple analytes (proteins, nucleic acids, carbohydrates, polysaccharides, lipids) simultaneously in a single sample. The system comprises a solid support having multiple species of impregnated receptors (e.g., antigen, antibody); a signal-producing system consisting of a labeled probe (e.g., peroxidase-labeled antibody) to bind to the analyte, or an unlabeled probe and a labeled anti-probe; a quality control system for monitoring the assay components; and (when probe binding is detected by a color reaction) a std. color scale which is developed similarly during the assay to provide quant. data. An app. is also described with different compartments for various stages of the assay (e.g., incubation, wash, etc.).

L1 ANSWER 11 OF 16 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1985:200726 HCAPLUS
DOCUMENT NUMBER: 102:200726
TITLE: Modified sheet of material and using same in connection with biochemical procedures
INVENTOR(S): Herzberg, Max; **Fish, Falk**
PATENT ASSIGNEE(S): Orgenics Ltd., Israel
SOURCE: Eur. Pat. Appl., 16 pp.

CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 136153	A2	19850403	EP 1984-306393	19840919
EP 136153	A3	19860122		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4549011	A	19851022	US 1983-533770	19830919
IL 72899	A1	19910415	IL 1984-72899	19840910
JP 60155973	A2	19850816	JP 1984-197758	19840919
ES 536059	A1	19860401	ES 1984-536059	19840919
ES 545824	A1	19860116	ES 1985-545824	19850801

PRIORITY APPLN. INFO.: US 1983-533770 19830919

AB A sheet is described for sepg. and retaining biol. mols. The sheet is activated with a compd. (e.g., cyanuric chloride) for covalently binding a ligand to such sheet, and then coated with ligands having an affinity for the substance of interest. A method of using the sheet for isolating and sepg. substances of interest and methods for forming the sheet are described. Thus, sheets were used for identification of specific antigen from a crude prepn. of Newcastle virus, for identification and purifn. of poly(A)-binding proteins, and for identification of SV40 virus, as examples.

L1 ANSWER 12 OF 16 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1984:172803 HCAPLUS
DOCUMENT NUMBER: 100:172803
TITLE: Proliferative response of immune mouse T-lymphocytes to the lymphocytosis-promoting factor of Bordetella pertussis
AUTHOR(S): **Fish, Falk**; Cowell, James L.; Manclark, Cahrles R.
CORPORATE SOURCE: Food Drug Adm., Natl. Cent. Drugs Biol., Bethesda, MD, 20205, USA
SOURCE: Infect. Immun. (1984), 44(1), 1-6
CODEN: INFIBR; ISSN: 0019-9567
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Immunization of mice with a whole-cell pertussis vaccine or with the purified, detoxified lymphocytosis-promoting factor (LPF) of B. pertussis resulted in an increased in vitro proliferative response to LPF in immune lymph node cells. The proliferative response was detected above the nonspecific mitogenic activity of LPF. That the proliferative response of the immune lymph node cells was a demonstration of a specific cell-mediated immunity to LPF was supported by the following: (i) the specificity of the response to the immunizing antigen; (ii) the ability of chem. modified, nonmitogenic LPF to induce proliferation in immune lymph node cells; and (iii) a dependence on T-cells for the demonstration of the proliferative response of immune cells to LPF. Immunization of mice with protective doses of detoxified LPF resulted in serum antibody and cell-mediated responses to LPF. Immunization of mice with protective

doses of whole-cell pertussis vaccine resulted in a cell-mediated response but not a detectable antibody response to LPF. The LPF of B. pertussis may play an important role in pathogenesis and immunity in pertussis, and the demonstration of a cell-mediated immune response to LPF suggests a possible role for cell-mediated immunity to LPF in protection from pertussis disease.

L1 ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1984:18993 HCAPLUS
DOCUMENT NUMBER: 100:18993
TITLE: Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase
AUTHOR(S): Sekura, Ronald D.; **Fish, Falk**; Manclark, Charles R.; Meade, Bruce; Zhang, Yan Ling
CORPORATE SOURCE: Off. Biol., Food and Drug Adm., Bethesda, MD, 20205, USA
SOURCE: J. Biol. Chem. (1983), 258(23), 14647-51
CODEN: JBCHA3; ISSN: 0021-9258
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Pertussis toxin, the major toxin produced by Bordetella pertussis, catalyzes the ADP-ribosylation of a specific membrane polypeptide which appears to be involved in regulation of the catalytic subunit of adenylate cyclase. A rapid purifn. procedure was developed for the prepn. of pertussis toxin in high yields. Through the sequential use of the affinity matrixes, Affi-Gel blue and fetuin-Sepharose 4B, milligram quantities of apparently homogeneous toxin can be prepd. from the culture supernatants of B. pertussis strain 165. Structural, amino acid, and immunol. analyses indicate that toxin prepd. from strain 165 is indistinguishable from toxin prepd. from other strains. Activation of the ADP-ribosyltransferase activity requires treatment of the toxin with a thiol reducing agent. This activation appears to be assocd. with the redn. of intrachain S-S bonds present in the catalytic subunit. Activated toxin prepns. catalyzed ADP-ribosylation of a protein (mol. wt. = 40,000) present in cell membrane prepns. obtained from human red blood cells and platelets, rat adipocytes, and cyc-S49 cells which are deficient in the adenylate cyclase regulatory component which is the substrate for cholera toxin.

L1 ANSWER 14 OF 16 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1977:582328 HCAPLUS
DOCUMENT NUMBER: 87:182328
TITLE: Interaction between soluble immune complexes and glass-fiber filters
AUTHOR(S): **Fish, Falk**
CORPORATE SOURCE: Dr. George S. Wise Life Sci. Cent., Tel Aviv Univ., Tel Aviv, Israel
SOURCE: J. Immunol. Methods (1977), 17(1-2), 21-9
CODEN: JIMMBG
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The 2 components of sol. antigen-antibody complexes, at the antigen excess, exhibit an increase in their binding ability to glass-fiber filters. In the bovine serum albumin (BSA) labeled with 125I anti-BSA

system the proportion of BSA-125I bound to the filter is markedly increased in the presence of anti-BSA antibodies. More than 80% of the antibody bound BSA can be removed by passage through the filter. In the other system, mouse .gamma.-globulin (MGG) anti-MGG-125I the proportion of antibody bound to the filter increases with the increase in antigen concn., while the presence of another, non-related, .gamma.-globulin has little effect on the binding. Possible mechanisms for binding of the sol. complexes to the glass-fiber filters are discussed.

L1 ANSWER 15 OF 16 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1975:153508 HCAPLUS
DOCUMENT NUMBER: 82:153508
TITLE: Incorporation of 125I-iododeoxyuridine into target cells as an assay for cell immunity
AUTHOR(S): **Fish, Falk**; Yaakubovicz, Margalit; Witz, Isaac P.
CORPORATE SOURCE: Dr. George S. Wise Life Sci. Cent., Tel Aviv Univ., Tel Aviv, Israel
SOURCE: J. Natl. Cancer Inst. (1974), 53(6), 1743-7
CODEN: JNCIAM
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Cell immunity was assayed by measuring decrease of iododeoxyuridine-125I (125IUDR) uptake into target cells when incubated with sensitized effector cells. This method was suitable for target cells in monolayer or suspension cultures. A labeling regimen was used in which 125IUDR was added after a short exposure of the target cells to effector cells. This obviated the need to preplate the target cells in the culture vessel a day before or to prelabel them. This method was used successfully in allogeneic and syngeneic (tumor-specific) systems. In the syngeneic systems, lymph node cells (LNC) from mice with a syngeneic 3-methylcholanthrene-induced tumor inhibited 125IUDR incorporation into the corresponding tumor cells. LNC from mice with a different syngeneic 3-methylcholanthrene-induced tumor did not inhibit 125IUDR incorporation into the 1st tumor cells.

L1 ANSWER 16 OF 16 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1973:403675 HCAPLUS
DOCUMENT NUMBER: 79:3675
TITLE: Tumor-associated immunoglobulins. Nature of the association
AUTHOR(S): Witz, Isaac P.; Ran, Maya; **Fish, Falk**; Argov, Shmuel; Klein, George
CORPORATE SOURCE: Dep. Microbiol., Tel Aviv Univ., Tel Aviv, Israel
SOURCE: Nat. Cancer Inst., Monogr. (1972), No. 35, 37
CODEN: NCIMAV
DOCUMENT TYPE: Journal
LANGUAGE: English
AB It is shown that mouse tumor cells are coated in vivo with immunoglobulin (Ig), mainly of the IgG2 class. This process seems to require conditions favoring cellular metab. The Ig coat is shed when placed in vitro cultures, but it can be refixed by the cells. The Ig coat of tumor cells is partly composed of antitumor antibodies and partly of Ig fixed by tumor cells nonspecifically.